E-LIB Suche - Ergebnisse für: R. Motzer

1

Survival by depth of response and efficacy by International..:

V. Grünwald ; T. Powles ; E. Kopyltsov...
https://oncourology.abvpress.ru/oncur/article/view/1786/1493. , 2024

2

Nivolumab plus cabozantinib versus sunitinib for first-line..:

Powles, T ; Burotto, M ; Escudier, B...
Powles , T , Burotto , M , Escudier , B , Apolo , A B , Bourlon , M T , Shah , A Y , Suárez , C , Porta , C , Barrios , C H , Richardet , M , Gurney , H , Kessler , E R , Tomita , Y , Bedke , J , George , S , Scheffold , C , Wang , P , Fedorov , V , Motzer , R J & Choueiri , T K 2024 , ' Nivolumab plus cabozantinib versus sunitinib for first-line treatment of advanced renal cell carcinoma : extended follow-up from the phase III randomised CheckMate 9ER trial ' , ESMO Open , vol. 9 , no. 5 , 102994 , pp. 1-11 . https://doi.org/10.1016/j.esmoop.2024.102994. , 2024

Link: https://researchers.mq.e..

3

Phase 3 CLEAR study in patients with advanced renal cell ca..:

V. Grünwald ; T. Powles ; M. Eto...
https://oncourology.abvpress.ru/oncur/article/view/1810/1529. , 2024

Link: https://oncourology.abvp..

4

Characterization and management of adverse reactions from t..:

R. Motzer ; S. George ; J. R. Merchan...
https://oncourology.abvpress.ru/oncur/article/view/1711/1455. , 2023

Link: https://oncourology.abvp..

5

Quality-adjusted time without symptoms or toxicity (Q-TWiST..:

C. H. Lee ; Y. Wan ; A. Smith..
https://oncourology.abvpress.ru/oncur/article/view/1543. , 2022

Link: https://doi.org/10.17650..

6

Health-related quality-of-life outcomes in patients with ad..:

R. Motzer ; C. Porta ; B. Alekseev...
https://oncourology.abvpress.ru/oncur/article/view/1607/1366. , 2022

Link: https://oncourology.abvp..

7

Health-related quality-of-life outcomes in patients with ad..:

R. Motzer ; C. Porta ; B. Alekseev...
https://oncourology.abvpress.ru/oncur/article/view/1607. , 2022

Link: https://doi.org/10.17650..

8

Quality-adjusted time without symptoms or toxicity (Q-TWiST..:

C. Lee H ; Y. Wan ; A. Smith...
https://oncourology.abvpress.ru/oncur/article/view/1543/1318. , 2022

Link: https://oncourology.abvp..

9

CheckMate-9ER-Studie: Nivolumab + Cabozantinib im Vergleich..:

Bedke, J ; Choueiri, T ; Powles, T...
http://dx.doi.org/10.3205/21swdgu23. , 2021

Link: https://doi.org/10.3205/..

10

Efficacy and correlative analyses of avelumab plus axitinib..:

Choueiri, T. K ; Larkin, J ; Pal, S...
http://eprints.gla.ac.uk/241286/1/241286.pdf. , 2021

Link: http://eprints.gla.ac.uk..

11

Updated efficacy results from the JAVELIN Renal 101 trial:f..:

Choueiri, T. K ; Motzer, R. J ; Rini, B. I...
Choueiri , T K , Motzer , R J , Rini , B I , Haanen , J , Campbell , M T , Venugopal , B , Kollmannsberger , C , Gravis-Mescam , G , Uemura , M , Lee , J L , Grimm , M O , Gurney , H , Schmidinger , M , Larkin , J , Atkins , M B , Pal , S K , Wang , J , Mariani , M , Krishnaswami , S , Cislo , P , Chudnovsky , A , Fowst , C , Huang , B , di Pietro , A & Albiges , L 2020 , ' Updated efficacy results from the JAVELIN Renal 101 trial : first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma ' , Annals of Oncology , vol. 31 , no. 8 , pp. 1030-1039 . https://doi.org/10.1016/j.annonc.2020.04.010. , 2020

Link: https://researchers.mq.e..

12

696O_PR Nivolumab + cabozantinib vs sunitinib in first-line..:

Choueiri, T.K ; Powles, T ; Burotto, M...
http://eprints.uanl.mx/22445/1/22445.pdf. , 2020

Link: http://eprints.uanl.mx/2..

13

Updated efficacy results from the JAVELIN Renal 101 trial: ..:

Choueiri, T K ; Motzer, R J ; Rini, B I...
https://eprints.gla.ac.uk/284663/1/284663.pdf. , 2020

Link: https://eprints.gla.ac.u..

14

A phase 3 study (COSMIC-313) of cabozantinib in combination..:

T. Choueiri ; L. Albiges ; T. Powles...
http://www.sciencedirect.com/science/article/pii/S2666168320362352. , 2020

Link: https://doi.org/10.1016/..

15

Lenvatinib plus everolimus or pembrolizumab versus sunitini..:

Grunwald V ; Powles T ; Choueiri T. K...
info:eu-repo/semantics/altIdentifier/pmid/30689402. , 2019

Link: http://hdl.handle.net/11..